Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST-001 plus best supportive care versus 5-fluorouracil/leucovorin plus best supportive care in biomarker-selected advanced pancreatic ductal adenocarcinoma
CTR20260974Phase 2Active
- Sponsor
- Accendatech
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Threonine in pancreatic adenocarcinoma (PDAC), sponsored by Accendatech. Started May 2026; status: active.
02
Drugs
Threonine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20260974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260974.